We’ve now reached 188 signatures—thank you to everyone who has signed, shared, and spoken out. Your support is building momentum, and we’re just getting started.
Today, we’ve expanded the petition to include a critical and urgent demand: Canada must fund clinical trials that combine antivirals and monoclonal antibodies to treat Long COVID.
There is growing scientific evidence that in some individuals, SARS-CoV-2 doesn’t fully clear—it lingers in tissues, possibly triggering ongoing inflammation, immune dysregulation, and damage. This is known as viral persistence, and it’s one of the leading hypotheses behind Long COVID.
Despite this, Canada has no active clinical trials targeting this mechanism with combination therapies—leaving hundreds of thousands of people suffering, unsupported, and without a roadmap to recovery.
Long COVID is not rare. It affects people of all ages, regardless of the severity of their initial infection. For many, it is life-changing. Yet the treatment landscape remains empty—and the silence from our public health institutions is deafening.
That’s why this petition now calls not only for urgent access to Pemgarda for prevention of COVID-19 in immunocompromised individuals, but also for a national research response to treat those already affected.
Next week, we’ll begin reaching out to leading health journalists across Canada to help bring this story to national attention. If you’re a journalist or know someone in media who may be interested, please get in touch.
Let’s keep going—because recovery should be possible.
Sign & share the petition:
https://www.change.org/MAbsForCanadaNOW
Thank you for standing with me and so many others still fighting for protection and care.
With gratitude,
Rowan
#BringPemgardaToCanada
#SupportLongCOVIDTrials
#ProtectImmunocompromised
#MAbsForCanadaNOW
#COVID19IsNotOver
Disclaimer: This update is for informational and advocacy purposes only and does not constitute medical or legal advice. For medical guidance, please consult a qualified healthcare provider. References to medications or regulatory processes do not imply endorsement or official affiliation with any companies or health agencies.